Zheyuan Technology Completes Nearly 200 Million Yuan in Series A2 Funding
Beijing Zheyuan Technology Co., Ltd. has successfully closed its Series A2 financing round, securing nearly 200 million RMB. The investment was led by Xiangxue Pharmaceutical, along with its industrial fund, and saw continued participation from existing shareholder China Science and Technology Venture Capital. Zhangjiang Hi-Tech Investment also joined as a co-investor. The newly acquired capital will be strategically allocated to foster the continuous development of high-value innovative intellectual property and to expand its global asset portfolio. Furthermore, the funds will support the enhancement of Zheyuan Technology's AI4S platform, which is driven by a life world model. This funding round signifies a significant step for the company in advancing its technological capabilities and market reach.
This Series A2 funding round for Zheyuan Technology highlights the growing investment in AI-driven platforms, particularly within the life sciences sector. The strategic allocation of funds towards intellectual property and global asset expansion suggests a long-term vision for market leadership. The involvement of both established industry players like Xiangxue Pharmaceutical and venture capital firms such as China Science and Technology Venture Capital indicates confidence in Zheyuan's technological approach and market potential. As AI4S platforms mature, their integration into scientific research and development could accelerate innovation cycles, potentially reshaping R&D investment strategies and competitive landscapes in the coming decade.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.
